European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
2025/09/18

European equities traded in the US as American depositary receipts were tracking higher Thursday morning, rising 0.71% to 1,554.06 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and pharmaceutical company Novo Nordisk (NVO), which climbed 8.3% and 6.6%, respectively. They were followed by 3D printer company Materialise (MTLS) and biopharmaceutical company Cellectis (CLLS), which advanced 4.5% and 4.1%, respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and telecommunications operator Telefonica (TEF), which fell 1.4% and 1.2%, respectively. They were followed by financial services company ING Group (ING) and petroleum refiner Equinor (EQNR), which were off 0.6% and 0.4%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Akari Therapeutics (AKTX), which rose 14% and 9%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company NuCana (NCNA), which were up 5.9% and 3.7%, respectively.

The decliners from the UK and Ireland were led by pharmaceutical company AstraZeneca (AZN) and tobacco company British American Tobacco (BTI), which dropped 1.9% and 1.8%, respectively. They were followed by telecommunications operator Vodafone Group (VOD) and mining company BHP Group (BHP), which were down 1.7% and 1.4%, respectively.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10